Results 31 to 40 of about 1,060,485 (284)
Biochemical and functional studies of a novel complement inhibitor, CRIT, with its interaction partners [PDF]
, 2005 Complement C2 receptor trispanning (CRIT), a three transmembrane receptor, was first discovered on the surface of the parasite Schistosoma haematobium and formerly termed Schistosoma trispanning orphan receptor (Sh-TOR). This receptor acts as decoy C2-
Hui, Kwok-Min
core +1 more source
The Role of Complement in Cancer Immunotherapy [PDF]
, 2022 The dual role of complement in both cancer development and treatment has been investigated extensively and is characterized by a substantial literature that documents the conditions in which complement can either enhance tumor growth or promote the ...
core +1 more source
Therapeutic Advances in Hematology, 2020 Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase ...
Hubert Schrezenmeier +11 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2022 Clinical signs arising from intravascular hemolysis, hemolysis-related transfusions and thrombosis are indications for treatment initiation in paroxysmal nocturnal hemoglobinuria (PNH), whereas clone size per se is not.
Semra AYDIN
doaj +1 more source
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment [PDF]
Kidney International, 2021 Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome.
Gema Ariceta +19 more
openaire +4 more sources
Paths reunited: initiation of the classical and lectin pathways of complement activation [PDF]
, 2010 Understanding the structural organisation and mode of action of the initiating complex of the classical pathway of complement activation (C1) has been a central goal in complement biology since its isolation almost 50 years ago.
Schmid, Ralf +9 more
core +1 more source
Biomedicines, 2022 Introduction: immune-mediated necrotising myopathy (IMNM) is associated with pathogenic anti-signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, at least partly through activation of the classical pathway of ...
Sarah Julien +13 more
doaj +1 more source
Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b [PDF]
, 2012 Upon host infection, the human pathogenic microbe Staphylococcus aureus (S. aureus) immediately faces innate immune reactions such as the activated complement system. Here, a novel innate immune evasion strategy of S. aureus is described.
Peter F. Zipfel +17 more
core +1 more source
C3 Glomerulopathy and Therapeutic Potential of C5 Complement Inhibitors
Open Journal of Nephrology, 2016 C3 glomerulopathy is a disease including both dense deposit disease and C3 glomerulonephritis has an estimated prevalence of 2 to 3 per million. Originally, these pathologies were defined as glomerular pathology characterized by accumulation of C3 with absent or scanty immunoglobulin deposition.
Aysam Mahmoud +3 more
openaire +2 more sources
Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice [PDF]
, 2010 The motor axonal variant of Guillain-Barré syndrome is associated with anti-GD1a immunoglobulin antibodies, which are believed to be the pathogenic factor. In previous studies we have demonstrated the motor terminal to be a vulnerable site.
Halstead, S. +7 more
core +2 more sources